WHO and NIDA Want CBD Approved for Medicinal Purposes

WHO and NIDA Want CBD Approved for Medicinal Purposes
February 21, 2020 Hugs CBD
In CBD Industry
who and NIDA on CBD

Wellness is a word that practically embraces the soul. It connotes healthcare, but it engenders so much more. We all strive to be well – not just physically fit, but emotionally vibrant and spiritually whole, as well. 

Since we all have the same general goals in mind, it is surprising that several major organizations disagree about the concept of wellness in relation to CBD. Cannabidiol is the full scientific name of CBD, and it does not produce any of the psychological effects associated with tetrahydrocannabinol (THC).

So, what are the benefits of CBD? The answer depends on whom you ask. 


The WHO (World Health Organization) is a branch of the United Nations concerned with global wellness. They strive to fight cancer, HIV, and influenza in an effort to raise life expectancies across the planet. As part of WHO’s perspective, they published a comprehensive report on the uses, side effects, and potential medicinal breakthroughs presented by CBD.

The WHO studied 15 patients being treated for epilepsy with a daily dose of CDB, measuring between 200 and 300 milligrams. Half of the study was administered a placebo, so only eight of the participants experienced the benefits of cannabidiol. According to the WHO’s findings, four of these eight had almost no epileptic activity during the trial period. Another three recipients showed marginal improvement, meaning only one of the eight patients taking CBD found it ineffective to subdue their seizures. 

In addition to these remarkable results, the WHO report concluded, “CBD was tolerated in all patients, with no signs of toxicity or serious side effects.” The World Health Organization characterized CBD as a safe substance whose main adverse effects may be a result of interactions with other drugs. In fact, the WHO went on to assert that, “To date, there is no evidence of recreational use of CBD or any public health-related problems associated with the use of pure CBD.”


The positive findings of the WHO were echoed by the National Institute on Drug Abuse, or NIDA. This federally funded research studies the science behind addiction and substance abuse, and their Director is a woman named Nora Volkow. In an article for the Huffington Post, Volkow argued that CBD does not affect the brain’s receptors in the way that psychotropic elements like THC do. In fact, she posited the theory that CBD may actually mitigate – or mellow – the “high” often associated with THC.

But Volkow didn’t stop there. She not only regards CBD as “a safe drug with no addictive effects,” but she also heralds it as an element that “may be poised to make great inroads into our pharmacopeia.” Volkow mentions how CBD could have immense therapeutic value to treat a wide array of afflictions before vowing to address “barriers that slow clinical research with CBD.”

What could be responsible for such barriers? Meet the United States Food and Drug Administration.


In comparison to the aforementioned organizations, the Food & Drug Administration (FDA) is a veritable dinosaur in regards to CBD adoption and understanding. While it is true that the FDA has approved one CBD product, they are hesitant to explore the further medicinal benefits of the compound. 

Epidiolex has been shown to drastically reduce epileptic episodes, even in patients with Dravet syndrome, a rare genetic disorder that induces fevers and violent seizures. Dravet syndrome can be so disruptive that it prevents children from developing motor skills and language proficiency. 

CBD has also been FDA-approved to treat individuals suffering from Lennox-Gastaut syndrome, a condition so debilitating that it often results in intellectual impediments and learning disabilities. 

While it is encouraging to see the FDA admit to the life-changing benefits that cannabidiol can bring to those suffering from severe forms of epilepsy, the commissioner of the administration failed to make further progress. He warned that other research initiatives must prove that CBD was safe and effective before getting the green light to prescribe it for medicinal use.

Why hasn’t the commissioner spoken to his counterparts at the WHO or NIDA?

The FDA has put extreme limits on the federal use and regulation of marijuana in all forms, even the distilled, non-psychotropic strains of CBD discussed above. The agency does not condone its use as a supplement or dietary additive and warns against making claims about its curative properties.


Curiosity is the engine of progress. If we didn’t ask questions, then we would never get any answers. That is why it is so dismaying for the FDA to hold up further progress of CBD research for medicinal purposes.

Anecdotal evidence has suggested that CBD is phenomenally successful in lowering anxiety, but we welcome empirical data to catch up with what we already suspect. Whether blended with a relaxing beverage or applied directly to the skin in the form of a soothing balm, millions of consumers claim CBD products have delighted and calmed them.

While the FDA is a respected organization, many CBD consumers are confused by their inaction towards research. According to the statements issued by NIDA and WHO, cannabidiol summons a potentially new day in medicinal breakthroughs and the cessation of suffering. Their studies seemingly debunk certain claims that CBD may be unsafe or otherwise unstable. So, why is the FDA so slow to sing the praises of cannabidiol?It comes down to a question of regulation and perception. The FDA may not appreciate the wonders of CBD yet, but the times are rapidly transforming public opinion. Cannabidiol is already saving lives in the form of the already FDA-approved Epidiolex. To join the revelry of CBD positivity, contact HUGS and let us know how we can open minds, hearts, and endless possibilities by working together.

Comments (0)

Leave a reply

Your email address will not be published. Required fields are marked *